AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02012920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seviteronel: given orally once daily in 28 day cycles
Study NCT01775592 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Arterakin (DHA-PPQ)
Study NCT01315249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indacaterol and glycopyrronium (QVA149)
Description: QVA149 capsules delivered via dry powder inhaler (SDDPI), once daily.
Study NCT01315249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to fluticasone/salmeterol
Description: Placebo to fluticasone/salmeterol delivered via Accuhaler® device, twice daily.
Study NCT01315249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone/salmeterol
Description: Fluticasone/salmeterol dry inhalation powder delivered via Accuhaler® device, twice daily.
Study NCT01315249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to indacaterol and glycopyrronium (QVA149)
Description: Placebo to QVA149 delivered via dry powder inhaler (SDDPI), once daily
Study NCT03955536 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group A: Group routine cardiac rehabilitation program (RCRP)
Description: Patient education, Chest Physiotherapy, Abdominal and chest breathing, Bronchial hygiene techniques, Segmental breathing exercises, Triflow, exercise and mobilization,graduated exercise, positioning, active joint movement, moving inside bed, sitting at the edge of the bed, transfer from bed to chair, standing walking program, up and down stairs.~Evaluations for each patient (preoperative and just before discharge) Spirometric measurements Intraoral pressure measurementDyspnea assessment (BORG), Pain assessment (VAS), Evaluation of anxiety and depression (HAD) Evaluation of functional capacity (6 minutes walking test) Quality of Life (MacNew Heart Disease Specific Quality of Life Questionnaire)
Study NCT03955536 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group B: Group RCRP and inspiratory muscle training
Description: use of additional virtual reality goggles in the routine cardiac rehabilitation program Virtual reality glasses installed in the patient will feel the best way to feel an environment.~Virtual reality glasses are planned to be used 15 minutes by increasing the usage period.~Evaluations for each patient (preoperative and just before discharge) Spirometric measurements Intraoral pressure measurementDyspnea assessment (BORG), Pain assessment (VAS), Evaluation of anxiety and depression (HAD) Evaluation of functional capacity (6 minutes walking test) Quality of Life (MacNew Heart Disease Specific Quality of Life Questionnaire)
Study NCT03955536 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group C: Group RCRP and virtual reality application
Description: nspiratory muscle training with Threshold for routine cardiac rehabilitation Training intensity~- 30% of the maximum measured inspiratory pressure per week (15 min.). Every 10 breaths after rest.~Evaluations for each patient (preoperative and just before discharge) Spirometric measurements Intraoral pressure measurementDyspnea assessment (BORG), Pain assessment (VAS), Evaluation of anxiety and depression (HAD) Evaluation of functional capacity (6 minutes walking test) Quality of Life (MacNew Heart Disease Specific Quality of Life Questionnaire)
Study NCT02696681 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Integrating CBT for mental health and substance issues concern with CBT for health behavior change
Study NCT03174119 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Light therapy - active
Description: Active light will be used for one week, as compared to placebo light.
Study NCT03174119 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo light
Description: Placebo light will be used for one week, as compared to real light exposition.
Study NCT00870870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1000 milligrams per square meter (mg/m\^2) on Days 1 and 8 of each cycle~\[First 6 cycles (18 weeks)\]
Study NCT00870870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 milligrams per square meter (mg/m\^2) on Days 1 and 8 of each cycle~\[First 6 cycles (18 weeks)\]
Study NCT00870870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 75 mg/m\^2 on Day 1 of each cycle~\[First 6 cycles (18 weeks)\]
Study NCT00870870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m\^2 on Day 1 of each cycle~\[First 6 cycles (18 weeks)\]
Study NCT00870870 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-A12 (cixutumumab)
Description: 6 milligrams per kilogram (mg/kg) intravenous (IV) infusion, administered once per week (on Days 1, 8, and 15 of each cycle)~\[First 6 cycles (18 weeks)\]
Study NCT00870870 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: 400 mg/m\^2 IV infusion, administered on Day 1 of Cycle 1, 250 mg/m\^2 once per week thereafter~\[First 6 cycles (18 weeks)\]
Study NCT00870870 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 400 mg/m\^2 IV infusion, administered on Day 1 of Cycle 1, 250 mg/m\^2 once per week thereafter~\[First 6 cycles (18 weeks)\]
Study NCT00870870 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-A12 (cixutumumab)
Description: 10 mg/kg IV infusion, administered once every 2 weeks~(Maintenance therapy)
Study NCT00870870 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: 500 mg/m\^2 IV infusion, administered once every 2 weeks~(Maintenance therapy)
Study NCT00870870 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 500 mg/m\^2 IV infusion, administered once every 2 weeks~(Maintenance therapy)
Study NCT00870870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Area under the curve (AUC) = 5, Day 1 of each cycle~\[First 6 cycles (18 weeks)\]~\*Carboplatin will be replaced by Cisplatin
Study NCT00870870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Area under the curve (AUC) = 5, Day 1 of each cycle~\[First 6 cycles (18 weeks)\]~\*Carboplatin will be replaced by Cisplatin
Study NCT02354742 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Echo guided fluid resuscitation
Description: Patients will have their fluid resuscitation care guided by measurements obtained during an echo.
Study NCT02354742 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EGDT fluid resuscitation
Description: Patients will have their fluid resuscitation care guided by an EGDT protocol, which is currently used as standard of care.
Study NCT03025607 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JOOL Health Mobile Phone Application
Description: JOOL Health is a mobile phone-based application that aims to increase autonomous motivation to prevent T2DM by helping individuals make connections between certain health behaviors and the energy and willpower needed to achieve personal goals. On a daily basis, JOOL Health users chart the following health behaviors: Sleep, Presence, Activity, Creativity, and Eating. On a weekly basis, JOOL Health users are asked to record how well they lived according to their purpose and values. Through the integration of user-entered information with contextual data, JOOL Health provides tailored messaging and daily predictions of individuals' energy and willpower.
Study NCT03228095 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: VOC detection in breath and in skin headspace
Description: VOC will be detected in breath with off-line and on-line testing and in skin headspace with off-line testing
Study NCT03228095 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Breath sampling
Description: Breath sampling for VOCs detections will be carried out using nano-sensor based devices (electronic nose)
Study NCT03228095 — intervention group
Intervention type: PROCEDURE
Intervention: Upper endoscopy with biopsies
Description: Upper endoscopy with proper biopsy work-up will be used for identification and stratification of gastric lesions as well as acquisition of biopsies for microbiota testing
Study NCT03228095 — intervention group
Intervention type: PROCEDURE
Intervention: Colonoscopy with biopsies
Description: Colonoscopy with proper biopsy or polypectomy material work-up will be used for identification and stratification of colorectal lesions as well as acquisition of biopsies for microbiota testing
Study NCT03228095 — intervention group
Intervention type: PROCEDURE
Intervention: Whole blood/ Plasma / serum sampling
Description: Whole blood/Plasma/serum sampling will be used to obtain information for group stratification
Study NCT03228095 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Faecal sampling
Description: Facal samples will be obtained for faecal occult blood testing as well as microbiota analysis
Study NCT03228095 — intervention group
Intervention type: PROCEDURE
Intervention: Histological examination of surgical specimen
Description: Routine histological exam for patients undergoing curative or palliative surgery. Indication for surgery are set based on underlying condition. Study does not interfere with decision making for surgical treatment
Study NCT03228095 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Headspace analysis for biological material
Description: VOC analysis from headspace of surgical specimen, biopsy materials, blood/plasma, microbiota etc.
Study NCT04033809 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multigrain powder (S)
Description: A twice daily high fiber multigrain powder supplementation for 12 weeks
Study NCT01365650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Tromethamine
Description: Single intranasal dose of 30 mg ketorolac tromethamine (one 15 mg spray into each nostril) on Day 1 of Period 1
Study NCT01365650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxymetazoline Hydrochloride
Description: Single intranasal dose of oxymetazoline hydrochloride followed by a single intranasal dose of 30 mg ketorolac tromethamine (one 15 mg spray into each nostril) 30 minutes later on Day 1 of Period 2
Study NCT01365650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate
Description: Seven days of treatment with intranasal fluticasone propionate (between Periods 2 and 3) followed by a single intranasal dose of 30 mg ketorolac tromethamine (one 15 mg spray into each nostril) on Day 1 of Period 3
Study NCT00841100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kuvan
Description: 20mg/kg by mouth once daily
Study NCT00841100 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: Phenylalanine-restricted diet (4-10 mg/kg/day phenylalanine) using the prescribed phenylalanine-free medical formula and low protein foods tested with the patients for taste and acceptance to lower blood phenylalanine levels below 600 umol/l.
Study NCT03331042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM-1
Description: 3-drug combination product containing 50-mg diphenhydramine, 5-mg delayed-release zolpidem and 0.5-mg delayed-release lorazepam.
Study NCT03331042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D+Z
Description: 2-drug combination comparator product containing 50-mg diphenhydramine and 5-mg delayed-release zolpidem.
Study NCT03331042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D+L
Description: 2-drug combination comparator product containing 50-mg diphenhydramine and 0.5-mg delayed-release lorazepam.
Study NCT03331042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Identical in appearance to SM-1, D+Z and D+L and has the same excipients, but no diphenhydramine, zolpidem, lorazepam or delayed-release coating materials.
Study NCT03107468 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mokhuri intensive treatment
Description: Patients in this arm will be treated with acupuncture, Chuna and patient consultation during 5 weeks. For acupuncture therapy, disposable sterile needles will be placed on LI4, ST36, LV3, B22, B23, B24 and B25 of both sides of a patient for 15 minutes. For Chuna therapy, the patient lies on the Ergo Style™ FX-5820 Table in the prone position and back muscles will be relaxed by manual manipulation during flexion and extension movement of the table for 5 to 6 minutes. Patient consultation regarding the precautions for everyday life, the precautions for activity in bed, the precautions for walking, the precautions for particular movements and the exercises will be offered for 5 minutes.
Study NCT03107468 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical conventional standard treatment
Description: Patients in this arm will be treated with 10 sessions of non-surgical conventional standard treatment including conventional drug treatment and injection treatment under the consultation of neurosurgeons or doctors of anesthesiology or rehabilitation medicine during 5 weeks. For drug therapy, muscle relaxants, NSAIDs, gabapentin, pregabalin or tricyclic antidepressants will be prescribe. For epidural steroid injection, 3cc of epidurals will be injected at the affected lesion once or twice. For physical therapy, participants shall participate in conventional physical therapy with the aid of physical therapists, including heating pad, deep tissue heating device and transcutaneous electrical nerve stimulation (TENS) twice a week during the five weeks of participation.
Study NCT04433390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxegol
Description: one naloxegol 12.5 mg tablet will be administrated 2 hours before surgery. One 25 mg naloxegol tablet per day will be administrated from 24h post-surgery until bowel movement; for maximum 5 days.
Study NCT04433390 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: inert tablet
Description: one inert tablet will be administrated 2 hours before surgery. One inert tablet per day will be administrated from 24h post-surgery until bowel movement; for maximum 5 days.
Study NCT03818945 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: shofu PRG barrier coat
Description: Trilaminar structure which forms a type of stable glass ionomer allowing ion release and recharge, while protecting the glass core from the damaging effects of moisture, greatly improving long-term durability.(Na, BO3, Al, SiO3, F,Sr)
Study NCT03818945 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sodium fluoride varnish
Description: 5% sodium fluoride \[22,600 ppm F-\]
Study NCT01818856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir withdrawal, atazanavir 200 mg/12h
Study NCT01818856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir interactions
Study NCT01475838 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PI
Description: PI administered according to prescribing information; allowed PIs include atazanavir (ATV), darunavir (DRV), fosamprenavir (FPV), lopinavir (LPV), or saquinavir (SQV)
Study NCT01475838 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RTV
Description: RTV administered according to prescribing information FTC/TDF administered according to prescribing information
Study NCT01475838 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FTC/TDF
Description: FTC/TDF (200/300 mg) administered according to prescribing information
Study NCT01475838 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stribild
Description: Stribild (E/C/F/TDF) (150/150/200/300 mg) STR administered orally once daily with food
Study NCT01475838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stribild
Description: Stribild (E/C/F/TDF) (150/150/200/300 mg) STR administered orally once daily with food
Study NCT03482063 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Swisse Ultiboost Memory + Focus
Description: B vitamins help energy release, help with metabolism of food into energy, assist energy production and vitality.~Vitamin B5 helps support normal mental performance. Brahmi, Ginkgo, Vitamin B12 and B3 help support brain function. Ginkgo helps maintain healthy circulation and delivery of oxygenated blood to the brain.~Brahmi supports memory function and recall. Vitamin B5, B6 are important for adrenal function, assist adrenal glands during stress periods.~Vitamin B2, B3, B5, B6, B12 help relieve tiredness and fatigue.
Study NCT03482063 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: riboflavin (2.2mg)
Study NCT04066361 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chatbot
Description: Interactive text chat designed to mirror the educational components of a traditional genetic counseling visit
Study NCT04066361 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Education
Description: Brief video designed to mirror the educational components of a traditional genetic counseling visit
Study NCT04347837 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Titan SGS stapler
Description: Stapler for the longitudinal resection of the stomach
Study NCT03913806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab-IRDye800CW
Description: dose finding:10mg; 25mg; 50mg
Study NCT04012697 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Support
Description: Participants randomized to the intervention group will be seen by the peer support worker during their stay in the emergency department. The goal of the peer support worker's practice is to address the participant's wellness from a holistic point of view that includes their relationships, connections to the community, general well-being, and sense of empowerment, with an overall focus on quality-of-life goals (Sunderland et al., 2013). The peer support worker will provide a multi-faceted intervention, which aims to foster a peer-to-peer relationship encompassing elements of empathic communication, brief supportive counseling, advocacy for non-medical needs in hospital, liaising and collaborating with medical and nursing staff, motivational interviewing, and connection with programs in the community.
Study NCT02945215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI301
Description: IBI301 375mg/㎡
Study NCT02945215 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab 375mg/㎡
Study NCT03203915 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chardonnay grape marc marc high polyphenol dose (120mg)
Description: 3 prepackaged capsules taken once in the morning with meal for 3 weeks. The total dose will be 120mg of total polyphenols
Study NCT03203915 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chardonnay grape marc powder low polyphenol dose (75mg)
Description: 3 prepackaged capsules taken once in the morning with meal for 3 weeks. The total dose will be 75mg of total polyphenols
Study NCT03203915 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo (0mg)
Description: 3 prepackaged capsules taken once in the morning with meal for 3 weeks. The total dose will be 0mg of polyphenols
Study NCT02339766 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus Lumborum Block
Description: Quadratus Lumborum Block with Ropivacaine 0.5% will be done.
Study NCT02339766 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Block
Description: Sham block of Quadratus Lumborum will be done with Saline.
Study NCT02339766 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Intrathecal Morphine
Description: Intrathecal Morphine 150 mcg will be co-administered with the spinal anesthetic.
Study NCT02339766 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal Morphine
Description: Intrathecal Morphine 150 mcg will be co-administered with the spinal anesthetic.
Study NCT02339766 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal Saline
Description: Intrathecal Saline 0.15 mL will be co-administered with the spinal anesthetic.
Study NCT02929979 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: Participants will complete 22.5 hours of cognitive training exercises over 6-weeks (training 5 times a week) using an app-based program, BrainHQ (BPI/Posit Science, San Francisco). BrainHQ is based on a previous neuroscience-based cognitive training program shown to improve cognition in several different randomized controlled studies with other clinical populations. The investigators will use a suite of BrainHQ exercises designed to target and ameliorate cognitive disruptions in 4 cognitive domains (see main outcome). The investigators will employ basic exercises that focus on increasing processing efficiency in the auditory and visual perceptual and working memory domains, as well as exercises that target impulsivity and cognitive biases. Exercises will be packaged into 4 modules (attention skills, memory skills, executive functioning skills, cognitive control skills) comprised of 4 exercises each. All participants will progress through the same fixed schedule of modules.
Study NCT02929979 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive training placebo control
Description: Participants will play a rotating set of commercial computer games at the same dose and frequency as the cognitive training. The investigators selected this control activity because it mirrors the game-like properties of the cognitive training and it will be used to control for contact with research personnel and for the non-specific effects of participant motivation and engagement with daily computerized activities. It also allows for a double blind study design. Games from the website Sporcle will be used and an online account can be created for each participant.
Study NCT01985802 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pacing